Health Plan Enrollment and Disenrollment of Individuals With and Without Established Chronic Disease in a US Commercially Insured and Medicare Advantage Population

被引:7
|
作者
Chung, Haechung [1 ]
Deshpande, Gaurav [1 ]
Zolotarjova, Julia [1 ]
Quimbo, Ralph A. [1 ]
Kern, David M. [2 ]
Cochetti, Philip T. [3 ]
Willey, Vincent J. [1 ]
机构
[1] HealthCore, 123 Justison St,Ste 200, Wilmington, DE 19801 USA
[2] Janssen Res & Dev, Titusville, NJ USA
[3] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
来源
关键词
INSURANCE-COVERAGE; CARE UTILIZATION; MANAGED CARE; READMISSIONS; COSTS;
D O I
10.18553/jmcp.2019.25.5.612
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Chronic disease is associated with increased health care resource utilization and costs. Effective development and implementation of health care management and clinical intervention programs require an understanding of health plan member enrollment and disenrollment behavior. OBJECTIVE: To examine the health plan enrollment and disenrollment behavior of commercially insured and Medicare Advantage members with established chronic disease compared with matched members without the disease of interest, using data from a large national health insurer in the United States. METHODS: This retrospective matched cohort study used administrative claims data from the HealthCore Integrated Research Database from January 1, 2006, to November 30, 2015, to identify adults with chronic disease (type 2 diabetes mellitus [T2DM], cardiovascular disease [CVD], chronic obstructive pulmonary disease [COPD], rheumatoid arthritis [RA], and breast cancer [BC]). Members with no established chronic disease (controls) were directly matched to members with established chronic disease (cases) on demographic characteristics. The earliest date on which members met the criteria for a given disease was defined as the index date. Controls had the same index date as the matched cases. All members had >= 12 months of continuous health plan enrollment before the index date. Outcomes included health plan member disenrollment and enrollment duration. Incidence rates per 1,000 member-years for member disenrollment were evaluated along with incidence rate ratios (relative risk) using a Poisson model. Time to disenrollment was analyzed by Cox proportional hazard models and Kaplan-Meier survival curves. Sensitivity analyses were conducted where death was included as a disenrollment event. RESULTS: 70,907 health plan members with BC (99.7% female, mean age 60.5 years); 28,883 members with COPD (52.3% female, mean age 66.7); 835,358 members with CVD (50.5% female, mean age 62.7 years); 210,936 members with T2DM (45.2% female, mean age 53.6 years); and 31,954 members with RA (72.0% female, mean age 55.5 years) were matched to controls and met the study criteria. The incidence rates of health plan disenrollment ranged from 155 to 192 members per 1,000 members per year. Compared with controls, members with chronic disease were 30%-40% less likely to disenroll from a health plan (P < 0.001 for all comparisons). Among those who disenrolled, enrollment duration ranged from 2.3 to 2.7 years among cases and 1.5 to 1.8 years among matched controls (P <= 0.001 for all comparisons). CONCLUSIONS: This real-world study demonstrated that members with chronic disease had a significantly lower rate of disenrollment and a longer duration of enrollment compared with matched controls and were continuously enrolled for almost a year longer than members without a diagnosed chronic disease. Understanding health plan enrollment and disenrollment behavior may provide a valuable context for determining the time frame for the effect of health care programs and initiatives. Copyright (C) 2019, Academy of Managed Care Pharmacy. All rights reserved.
引用
收藏
页码:612 / +
页数:11
相关论文
共 33 条
  • [1] Enrollment patterns and health in claims data for the commercially insured US population
    Teltsch, Dana Y.
    Cheever, Elizabeth
    Albright, Dawn G.
    Gierada, Monica
    Wyss, Richard
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 111 - 112
  • [2] Factors associated with health plan disenrollment during pregnancy among US commercially insured women
    Seals, Ryan M.
    Singla, Rishav
    Wang, Florence
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 524 - 524
  • [3] Mortality Ascertainment in a Medicare Advantage Population Using Health Plan Enrollment Data
    Suehs, Brandon
    Bowe, Andy
    Davis, Cralen
    Bunniran, Su
    Uribe, Claudia
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 306 - 307
  • [4] Comorbidity Burden Among Patients with CKD and Type 2 Diabetes in a US Commercially Insured/Medicare Advantage Population
    Chung, Haechung
    Thomas, Nicole M.
    Willey, Vincent
    Kong, Sheldon X.
    Singh, Rakesh
    Farej, Ryan
    Partridge, Jamie
    Elliott, Jay
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 276 - 276
  • [5] Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
    Dai, Dingwei
    Sharma, Ajay
    Phillips, Amy L.
    Lobo, Carroline
    [J]. JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (02): : 125 - 133
  • [6] Real-World Effectiveness of Oral Semaglutide (OS) from a US Commercially Insured and Medicare Advantage Population
    Shivappa, Nitin
    Swift, Caroline
    Noone, Joshua
    Du, Simo
    Radin, Michael
    Gamble, Cory
    Tan, Hiangkiat
    Willey, Vincent
    [J]. DIABETES, 2021, 70
  • [7] Chronic Conditions and Self-Reported Health in a Medicare Advantage Plan Population
    Guerard, Barbara
    Omachonu, Vincent
    Hernandez, S. Robert
    Sen, Bisakha
    [J]. POPULATION HEALTH MANAGEMENT, 2017, 20 (02) : 132 - 138
  • [8] ECONOMIC BURDEN AMONG CHRONIC KIDNEY DISEASE (CKD) PATIENTS WITH AND WITHOUT TYPE 2 DIABETES (T2D) IN A COMMERCIALLY INSURED/MEDICARE ADVANTAGE (MA) POPULATION IN THE UNITED STATES (US)
    Chung, H.
    Thomas, N.
    Willey, V
    Kong, S. X.
    Singh, R.
    Farej, R.
    Williamson, T.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S381 - S381
  • [9] Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Dang-Tan, Tam
    Paprocki, Yurek
    Willey, Vincent J.
    [J]. CLINICAL THERAPEUTICS, 2021, 43 (05) : 808 - 821
  • [10] Prevalence of comorbidities and multimorbidity among patients with atherosclerotic cardiovascular disease: A retrospective observational study in a large US commercially insured and Medicare advantage population
    Dai, Dingwei
    Fernandes, Joaquim
    Sun, Xiaowu
    Lupton, Laura L.
    Coetzer, Henriette
    Berk, Alexandra
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 257 - 257